Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions

BACKGROUND: Sorafenib is an orally administered multikinase inhibitor with antiangiogenic and antiproliferative properties. The results of large clinical trials demonstrate that sorafenib prolongs survival and the time to progression of patients with advanced hepatocellular carcinoma (HCC). The aim...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:BMC Cancer
Hoofdauteurs: Lee, Sae Hwan, Song, Il Han, Noh, Ran, Kang, Ha Yan, Kim, Suk Bae, Ko, Soon Young, Lee, Eoum Seok, Kim, Seok Hyun, Lee, Byung Seok, Kim, An Na, Chae, Hee Bok, Kim, Hong Soo, Lee, Tae Hee, Kang, Young Woo, Lee, Jae Dong, Lee, Heon Young
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: BioMed Central 2015
Onderwerpen:
Research Article
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4403976/
https://ncbi.nlm.nih.gov/pubmed/25885683
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-015-1273-2
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items